DK1750683T3 - Formuleringer med langvarig frigivelse - Google Patents

Formuleringer med langvarig frigivelse

Info

Publication number
DK1750683T3
DK1750683T3 DK05742315.4T DK05742315T DK1750683T3 DK 1750683 T3 DK1750683 T3 DK 1750683T3 DK 05742315 T DK05742315 T DK 05742315T DK 1750683 T3 DK1750683 T3 DK 1750683T3
Authority
DK
Denmark
Prior art keywords
prolonged
release formulations
formulations
release
Prior art date
Application number
DK05742315.4T
Other languages
English (en)
Inventor
Merrill S Goldenberg
Jian Hua Gu
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Application granted granted Critical
Publication of DK1750683T3 publication Critical patent/DK1750683T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
DK05742315.4T 2004-04-23 2005-04-25 Formuleringer med langvarig frigivelse DK1750683T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US56524704P 2004-04-23 2004-04-23
PCT/US2005/014254 WO2005105057A1 (en) 2004-04-23 2005-04-25 Sustained release formulations

Publications (1)

Publication Number Publication Date
DK1750683T3 true DK1750683T3 (da) 2013-04-15

Family

ID=34967842

Family Applications (1)

Application Number Title Priority Date Filing Date
DK05742315.4T DK1750683T3 (da) 2004-04-23 2005-04-25 Formuleringer med langvarig frigivelse

Country Status (16)

Country Link
US (2) US7323169B2 (da)
EP (1) EP1750683B1 (da)
JP (3) JP5036533B2 (da)
KR (1) KR101201638B1 (da)
CN (2) CN103920162B (da)
AU (1) AU2005237542B2 (da)
CA (1) CA2563185C (da)
DK (1) DK1750683T3 (da)
ES (1) ES2400687T3 (da)
HK (2) HK1103023A1 (da)
IL (1) IL178596A (da)
PL (1) PL1750683T3 (da)
PT (1) PT1750683E (da)
SI (1) SI1750683T1 (da)
WO (1) WO2005105057A1 (da)
ZA (1) ZA200609401B (da)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1750683T3 (pl) * 2004-04-23 2013-05-31 Amgen Inc Formuły o przedłużonym uwalnianiu
US20050271726A1 (en) * 2004-06-02 2005-12-08 Albert Crum Immune enhancing compositions and methods of use thereof
WO2006081171A1 (en) 2005-01-24 2006-08-03 Amgen Inc. Humanized anti-amyloid antibody
US7252834B2 (en) 2005-04-25 2007-08-07 Clemson University Research Foundation (Curf) Elastin stabilization of connective tissue
EP2441460A1 (en) * 2005-06-30 2012-04-18 Ipsen Pharma GLP-1 pharmaceutical compositions
AU2007237163A1 (en) * 2006-02-15 2007-10-18 Gammacan Ltd. Immunoglobulins from vitiligo plasma for melanoma therapy
ES2446266T3 (es) * 2006-07-21 2014-03-06 Amgen Inc. Método de detección y/o de medición de hepcidina en una muestra
US7947646B2 (en) 2007-03-06 2011-05-24 Amgen Inc. Variant activin receptor polypeptides
MX2009012609A (es) 2007-05-22 2009-12-07 Amgen Inc Composiciones y metodos para producir proteinas de fusion bioactivas.
US8414893B2 (en) 2007-12-21 2013-04-09 Amgen Inc. Anti-amyloid antibodies and uses thereof
US20090214654A1 (en) * 2008-02-21 2009-08-27 Isenburg Jason C Treatment of aneurysm with application of connective tissue stabilization agent in combination with a delivery vehicle
US20100016833A1 (en) * 2008-07-15 2010-01-21 Ogle Matthew F Devices for the Treatment of Vascular Aneurysm
US20100119605A1 (en) * 2008-11-12 2010-05-13 Isenburg Jason C Compositions for tissue stabilization
US8444624B2 (en) * 2009-10-19 2013-05-21 Vatrix Medical, Inc. Vascular medical devices with sealing elements and procedures for the treatment of isolated vessel sections
US8911468B2 (en) 2011-01-31 2014-12-16 Vatrix Medical, Inc. Devices, therapeutic compositions and corresponding percutaneous treatment methods for aortic dissection
CN103930437A (zh) 2011-03-16 2014-07-16 安姆根有限公司 Nav1.3和Nav1.7的强效及选择性抑制剂
JP2014516695A (ja) 2011-05-18 2014-07-17 バトリックス・メディカル・インコーポレイテッド 血管安定化用被覆バルーン
SG11201403367YA (en) 2011-12-19 2014-07-30 Amgen Inc Variant activin receptor polypeptides, alone or in combination with chemotherapy, and uses thereof
JP6426107B2 (ja) 2012-12-20 2018-11-21 アムジエン・インコーポレーテツド Ａｐｊ受容体アゴニストおよびその使用
MX2015009901A (es) 2013-02-01 2016-04-06 Santa Maria Biotherapeutics Inc Administración de un compuesto de antiactivina a a un sujeto.
UY35397A (es) 2013-03-12 2014-10-31 Amgen Inc INHIBIDORES POTENTES Y SELECTIVOS DE NaV1.7
JP6803236B2 (ja) 2014-06-10 2020-12-23 アムジェン インコーポレイテッド アペリンポリペプチド
TW201618783A (zh) 2014-08-07 2016-06-01 艾森塔製藥公司 以布魯頓(Bruton)氏酪胺酸激酶(BTK)佔據和BTK再合成速率為基礎之治療癌症、免疫和自體免疫疾病及發炎性疾病之方法
EP3634507A4 (en) * 2017-06-07 2021-03-24 EGY-Nano Pharma, LP PROLONGED ORAL DRUG DELIVERY PLATFORMS
KR20210068392A (ko) 2018-08-03 2021-06-09 넥테로 메디칼, 인크. 정제된 펜타갈로일 글루코스 및 전달하기 위한 장치
WO2020227437A1 (en) 2019-05-06 2020-11-12 Axial Biotherapeutics, Inc. Sustained release solid dosage forms for modulating the colonic microbiome

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2849370A (en) * 1953-06-04 1958-08-26 Novo Terapeutisk Labortorium A Injectable insulin preparations with protracted effect and process of producing same
GB929406A (en) * 1958-12-22 1963-06-19 Upjohn Co A process for the production of encapsulated material
CH498653A (fr) * 1968-03-29 1970-11-15 Kobayashi Takehiko Procédé d'encapsulation de matières hydrophobes
GB2209937B (en) * 1987-09-21 1991-07-03 Depiopharm S A Water insoluble polypeptides
US5151265A (en) * 1987-11-03 1992-09-29 Genentech, Inc. Gamma interferon formulation
US5019400A (en) * 1989-05-01 1991-05-28 Enzytech, Inc. Very low temperature casting of controlled release microspheres
WO1994008599A1 (en) * 1992-10-14 1994-04-28 The Regents Of The University Of Colorado Ion-pairing of drugs for improved efficacy and delivery
JP2744572B2 (ja) * 1993-02-17 1998-04-28 鐘紡株式会社 ポリフェノール化合物含有皮膚外用剤組成物の変色防止方法
JPH06345668A (ja) * 1993-06-07 1994-12-20 Shibayagi:Kk 感染防御組成物およびその用途
US5922253A (en) * 1995-05-18 1999-07-13 Alkermes Controlled Therapeutics, Inc. Production scale method of forming microparticles
EP0850051A2 (en) * 1995-08-31 1998-07-01 Alkermes Controlled Therapeutics, Inc. Composition for sustained release of an agent
WO1998010649A1 (en) 1996-09-13 1998-03-19 University Technology Corporation Biocompatible cationic detergents and uses therefor
US20030190307A1 (en) * 1996-12-24 2003-10-09 Biogen, Inc. Stable liquid interferon formulations
US6531154B1 (en) * 1997-06-10 2003-03-11 Brown University Research Foundation Modulated release from biocompatible polymers
JP2001510788A (ja) * 1997-07-23 2001-08-07 ペリオ プロダクツ リミテッド 薬学的薬剤を薬学的に口腔内に制御放出するためのタンニン酸ポリマー組成物
US5962522A (en) * 1997-09-05 1999-10-05 Avmax, Inc. Propyl gallate to increase bioavailability of orally administered pharmaceutical compounds
US6180666B1 (en) 1997-09-05 2001-01-30 Anmax, Inc. Use of gallic acid esters to increase bioavailability of orally administered pharmaceutical compounds
US6613358B2 (en) * 1998-03-18 2003-09-02 Theodore W. Randolph Sustained-release composition including amorphous polymer
ATE281155T1 (de) * 1998-04-20 2004-11-15 Genzyme Corp Medikamentöse verabreichung von proteinen aus polymergemischen
JP2000080027A (ja) * 1998-09-02 2000-03-21 Taiyo Kagaku Co Ltd 徐放性製剤
US6428818B1 (en) * 1999-03-30 2002-08-06 Purdue Research Foundation Tea catechin formulations and processes for making same
AU1360901A (en) 1999-11-01 2001-05-14 University Technology Corporation Compositions and methods for controlled-release delivery and increased potency of pharmaceuticals via hydrophobic ion-pairing
US6713506B2 (en) * 2000-10-11 2004-03-30 University Of South Florida Tea polyphenol esters and analogs thereof for cancer prevention and treatment
WO2002067966A1 (en) * 2001-02-22 2002-09-06 Purdue Research Foundation Compositions based on vanilloid-catechin synergies for prevention and treatment of cancer
JP5013152B2 (ja) * 2001-02-28 2012-08-29 株式会社ビーエムジー 蛋白質複合体形成剤
US20040142048A1 (en) * 2002-02-22 2004-07-22 Morre Dorothy M. Compositions based on proanthocyanadin-catechin synergies for prevention and treatment of cancer
CN1668212A (zh) * 2002-07-26 2005-09-14 帝斯曼知识产权资产管理有限公司 包含乳铁蛋白的组合物
US8912174B2 (en) * 2003-04-16 2014-12-16 Mylan Pharmaceuticals Inc. Formulations and methods for treating rhinosinusitis
US7605120B2 (en) * 2003-10-22 2009-10-20 Amgen Inc. Antagonists of the brandykinin B1 receptor
PL1750683T3 (pl) * 2004-04-23 2013-05-31 Amgen Inc Formuły o przedłużonym uwalnianiu

Also Published As

Publication number Publication date
IL178596A (en) 2012-06-28
US7323169B2 (en) 2008-01-29
US20050271722A1 (en) 2005-12-08
ZA200609401B (en) 2008-05-28
SI1750683T1 (sl) 2013-04-30
PL1750683T3 (pl) 2013-05-31
AU2005237542A1 (en) 2005-11-10
CN103920162B (zh) 2017-07-11
JP2012046520A (ja) 2012-03-08
KR20070026457A (ko) 2007-03-08
JP5829870B2 (ja) 2015-12-09
US20070292506A1 (en) 2007-12-20
JP5036533B2 (ja) 2012-09-26
CN1997356A (zh) 2007-07-11
US7732399B2 (en) 2010-06-08
AU2005237542B2 (en) 2009-12-17
CA2563185C (en) 2010-04-20
KR101201638B1 (ko) 2012-11-15
CN103920162A (zh) 2014-07-16
HK1103023A1 (en) 2007-12-14
HK1200092A1 (en) 2015-07-31
IL178596A0 (en) 2007-02-11
JP2012036194A (ja) 2012-02-23
ES2400687T3 (es) 2013-04-11
JP2007534698A (ja) 2007-11-29
PT1750683E (pt) 2013-01-25
EP1750683B1 (en) 2013-01-09
WO2005105057A1 (en) 2005-11-10
CA2563185A1 (en) 2005-11-10
EP1750683A1 (en) 2007-02-14

Similar Documents

Publication Publication Date Title
DK1750683T3 (da) Formuleringer med langvarig frigivelse
NO2019033I1 (no) regorafenib
DK1812025T3 (da) Stabiliserede bakteriofagformuleringer
DE602005021602D1 (de) Neigungsverstellvorrichtung
NO20075628L (no) Farmasøytiske formuleringer
BRPI0511900A (pt) composições farmacêuticas
DK1725218T3 (da) Farmaceutisk sammensætning omfattende pimobendan
DE602005021745D1 (de) Neigungsverstellvorrichtung
DK1804871T3 (da) Forbedret mellemstykke
DE602005018315D1 (de) Rollstuhl
IS8309A (is) Lyfjablöndur
DE602005023894D1 (de) Rücklehnvorrichtung
DK1778723T3 (da) Il-1-antagonistformuleringer
DE602005012474D1 (de) Bilderzeugung
DE602005014339D1 (de) Ür
ITMI20041447A1 (it) Composizione farmaceutica comprendente gabapentina
NO20042027L (no) Oral composition
ITBO20040302A1 (it) Riunito dentale
ITMI20040943A1 (it) Composizione farmaceutica cicatrizzante
ITMI20050457A1 (it) Pezzo sagomato
SE0403119D0 (sv) Therapeutic agents
SE0400718D0 (sv) Therapeutic agents
SE0400497D0 (sv) Artikulator
UA9750S (uk) Стілець
UA9726S (uk) Стілець